Invitation to Conference Call Regarding Acquisition of Serotec Group
Share:
MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX) will host a public conference call to discuss the acquisition of the Serotec Goup. Participants may listen via telephone. The call, which will be conducted in English, will be held today, on Thursday, January 12, 2006 at 10:30 a.m. CET.
Dial-in number: +49 (0)69 2222 2246 (listen-only)
Approx. 2 hours after the conclusion of the conference call, an audio replay of the conference will be available on www.morphosys.com - Events - Conference Calls
In case of any further questions please contact:
MorphoSys AG
Lena-Christ-Str. 48
82152 Martinsried/Planegg
Tel: +49 89 899 27 0
Fax: + 49 89 899 27 222
http://www.morphosys.com
Dr. Claudia Gutjahr-Löser
Director Corporate Communications
Tel: +49 89 899 27-122
Fax: + 49 89 899 27-5122
gutjahr-loeser@morphosys.com
Mario Brkulj
Manager Public Relations
Tel: +49 (0) 89 / 899 27-454
Fax: +49 (0) 89 / 899 27-5454
brkulj@morphosys.com
About MorphoSys:
MorphoSys develops and applies innovative technologies for the production of synthetic antibodies which accelerate drug discovery and target characterization. Founded in 1992, the Company's proprietary Human Combinatorial Antibody Library (HuCAL®) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing agreements and/or research collaborations with Bayer (Berkeley, California/USA), Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb (New Jersey/USA), Centocor Inc. (Malvern, Pennsylvania/USA), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Merck & Co., Inc. (New Jersey/USA), Novartis AG (Basel, Switzerland), Novoplant GmbH (Gatersleben, Germany), Pfizer Inc. (Delaware/USA), ProChon Biotech Ltd. (Rehovot/Israel), Schering AG (Berlin/Germany), Shionogi & Co., Ltd. (Osaka/Japan), Xoma Ltd. (Berkeley, California/USA) and others. Additionally, MorphoSys is active in the antibody research market through its Antibodies by Design business unit. Antibodies by Design was founded in 2003 for the purpose of exploiting the MorphoSys non-therapeutic antibody markets. MorphoSys' activities in the research antibody segment were significantly strengthened through the acquisition of the U.K. and U.S.-based Biogenesis Group in January 2005. For further information please visit the corporate website at: www.morphosys.com/.
To unsubscribe: http://www.huginonline.com/unsubscribe
